Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PCVX - Vaxcyte, Inc.

IEX Last Trade
82.61
-1.155   -1.398%

Share volume: 3,998
Last Updated: Fri 27 Dec 2024 05:30:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.39%

PREVIOUS CLOSE
CHG
CHG%
$83.76
-1.16
-1.38%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-1.34%
1 Month
-6.06%
3 Months
-22.91%
6 Months
14.47%
1 Year
37.88%
2 Year
84.08%
Key data
Stock price
$82.61
P/E Ratio 
0.00
DAY RANGE
$83.58 - $85.36
EPS 
$0.00
52 WEEK RANGE
$60.09 - $121.06
52 WEEK CHANGE
$35.70
MARKET CAP 
9.014 B
YIELD 
N/A
SHARES OUTSTANDING 
111.610 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
0.85
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,470,907
AVERAGE 30 VOLUME 
$1,067,144
Company detail
CEO: Grant E. Pickering
Region: US
Website: vaxcyte.com
Employees: 160
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials. The company was formerly known as SutroVax, Inc.

Recent news